- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03192046
Bracing for Walking in Parkinson's Disease
February 25, 2022 updated by: Staci Shearin, University of Texas Southwestern Medical Center
Impact of Carbon Fiber AFOs on Gait and Resulting Changes in Quality of Life Across Time in Persons With PD
Parkinson disease (PD) is a progressive neurological disease that results in characteristic gait dysfunction.
Gait problems include decreased velocity, decreased stride length, difficulty with initiation of gait, postural stability problems and alteration in joint kinematics.1 In this typically older patient population, these gait deviations affect their participation in household and community activities.
The standard of care is currently focused on therapeutic exercise and cueing of various types (visual, auditory, verbal).
Current interventions have not been demonstrated to markedly improve gait kinematics, so there is a need to identify interventions that could improve gait performance in this population.
Lower extremity bracing is a common and well-established intervention for gait dysfunction with other populations, including stroke and brain injury.
The braces allow for improved stability, sensory feedback, and consistent tactile cues to allow patients to have the best gait mechanics with each step.
It is reasonable to hypothesize that appropriate bracing may have the potential to improve gait function and kinematics in PD since these patient often have gastroc-soleus weakness.
Data from our early pilot studies indicates that bracing individuals with PD can positively impact their mobility.
This includes improvements in velocity, step length, and dynamic balance.
Additional data supported an upward trend in quality of life.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This is a randomized, repeated measures, matched group study.
There will be two groups of participants, 8 participants per group, 35 participants total from time of initial enrollment in this study.
Group one (G1) will receive bilateral custom braces and a standardized home walking/exercise program.
Group two will receive the standardized walking/exercise program without any brace or AFO.
Subjects will be randomized upon enrollment in the study.
At the time of consent, random drawing from concealed envelopes with red, blue or green chips will be done to determine group assignment.
Subjects will be recruited through the Clinical Center for Movement Disorders at UT Southwestern Medical Center where patients with PD receive routine evaluation and follow-up.
Subjects will be followed for 6 months during this study and outcome measures will be collected 3 times over the course of the study.
Subjects will be seen every 3 months for the duration of the study for testing as well as for other visits as noted in the table below.
Participants will not need to have insurance benefits for initial physical therapy evaluation and for ankle braces.
All subsequent visits to the Crowley gait lab for assessments and brace adjustment will be provided at no cost to the participants.
Study Type
Interventional
Enrollment (Actual)
10
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Texas
-
Dallas, Texas, United States, 75235
- UT Southwestern
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
30 years to 85 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Confirmed diagnosis of Parkinson's Disease according to the UK brain bank criteria.5
- Age between 30 and 85.
- Measurable decrement in gait velocity (between 35 and 15 percent below age-predicted norms for self-selected walking velocity) as measured by the 6 MWT
- Hoehn and Yahr stage 2-3.
- Less than 10 full heel raises in single limb stance bilaterally.
Exclusion Criteria:
- Body mass index greater than 40.
- Passive dorsiflexion range of motion less than approximately neutral (90 degrees)
- Any other uncontrolled health condition for which gait training is contraindicated
- Self-report of > 1 fall/month
- A score of 11 or less on the Short Orientation-Memory-Concentration Test of Cognitive Impairment
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Carbon Fiber Ankle Foot Orthosis (AFO)
For the bracing group, the participants will wear custom fabricated carbon fiber braces in addition to participating in a daily walking program and 7 visits of PT.
|
Custom AFOs in conjunction with a walking program, working up to walking 30 minutes 6 days a week.
|
ACTIVE_COMPARATOR: Control Group, Walking Program Only
The participants in this group will be prescribed a daily home walking walking program and 7 visits of PT.
|
standardized walking/exercise program without any brace or AFO
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Gait Capacity as Assessed b 6-Minute Walk Test
Time Frame: Baseline and 6 months
|
The 6 Minute Walk Test (6MWT) is a test of walking (gait) endurance and walking velocity and measures the distance a subject can walk indoors on a flat, hard surface in a period of 6 minutes, using assistive devices, as necessary.
The test is a reliable and valid evaluation of functional exercise capacity and is used as a sub-maximal test of aerobic capacity and endurance.
The test will be used to determine participant's gait efficiency at baseline and at 6 months.
While the total distance covered during six minutes (6MWTD) is often used as the standard measurement of gait capacity (i.e., the maximum distance one can achieve), the endurance (i.e., ability to maintain speed over a prolonged time) can be inferred by the gait speed trajectory (GST) during the 6MW test (6MWGST).
|
Baseline and 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Step Length
Time Frame: Baseline and 6 months
|
Participants will be asked to walk on a 12-16 foot long vinyl pad placed on the floor.
The mat will record and analyze step length.
|
Baseline and 6 months
|
Change in Temporal Spatial Gait Parameters Using the Computerized Gait Analysis System
Time Frame: Baseline and 6 months
|
Each subject will be asked to walk on a 12-16 foot long vinyl pad placed on the floor.
The mat will record and analyze temporal and spatial gait parameters.
|
Baseline and 6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Staci Shearin, Masters, UT Southwestern
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
September 1, 2016
Primary Completion (ACTUAL)
December 1, 2020
Study Completion (ACTUAL)
December 1, 2020
Study Registration Dates
First Submitted
June 13, 2017
First Submitted That Met QC Criteria
June 14, 2017
First Posted (ACTUAL)
June 19, 2017
Study Record Updates
Last Update Posted (ACTUAL)
March 23, 2022
Last Update Submitted That Met QC Criteria
February 25, 2022
Last Verified
February 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Neurologic Manifestations
- Parkinsonian Disorders
- Basal Ganglia Diseases
- Movement Disorders
- Synucleinopathies
- Neurodegenerative Diseases
- Parkinson Disease
- Nervous System Diseases
- Gait Disorders, Neurologic
- Anti-Infective Agents, Local
- Anti-Infective Agents
- Carbon Fiber
Other Study ID Numbers
- STU 012014-059
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson Disease
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedParkinson Disease 6, Early-Onset | Parkinson Disease (Autosomal Recessive, Early Onset) 7, Human | Parkinson Disease Autosomal Recessive, Early Onset | Parkinson Disease, Autosomal Recessive Early-Onset, Digenic, Pink1/Dj1United States
-
ProgenaBiomeRecruitingParkinson Disease | Parkinsons Disease With Dementia | Parkinson-Dementia Syndrome | Parkinson Disease 2 | Parkinson Disease 3 | Parkinson Disease 4United States
-
King's College LondonGlaxoSmithKlineCompletedParkinson Disease | Idiopathic Parkinson Disease | Parkinson Disease, PARK8United Kingdom
-
Ohio State UniversityCompletedParkinson's Disease | Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease | Parkinson Disease, Idiopathic | Parkinson's Disease, IdiopathicUnited States
-
National Yang Ming UniversityUnknownEarly Onset Parkinson Disease | Early Stage Parkinson Disease
-
Michele Tagliati, MDRecruitingREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Cedars-Sinai Medical CenterEnrolling by invitationREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Mahatma Gandhi Institute of Medical SciencesCompletedStroke, Parkinson' s Disease, Neurological Impairments, Tele-rehabilitationIndia
-
Merck Sharp & Dohme LLCCompletedParkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease
-
University of DeustoCompletedPARKINSON DISEASE (Disorder)Spain
Clinical Trials on Carbon Fiber Ankle Foot Orthosis (AFO)
-
University of IowaBio-Mechanical CompositesRecruitingHealthy | Lower Limb Injury | Post-Traumatic OsteoarthritisUnited States
-
University of IowaWithdrawnPost-traumatic Osteoarthritis | Ankle Fractures | Osteoarthritis AnkleUnited States
-
University of IowaFabtech SystemsNot yet recruitingTraumatic Lower Limb Injury
-
University of IowaRecruiting
-
Lieven De MaesschalckHandicap InternationalCompleted
-
Robert Jones and Agnes Hunt Orthopaedic and District...University of Nottingham; Keele UniversityNot yet recruiting
-
Medical College of WisconsinTerminated
-
Oslo University HospitalSophies Minde; NITO, Norwegian engineering and technology organiziationUnknownHemiplegic Cerebral Palsy | Cerebral Palsy, SpasticNorway
-
Innovative NeurotronicsCompleted
-
University College London HospitalsCompletedDistal Hereditary Motor Neuropathy, Type II | Distal Hereditary Motor Neuropathy, Type V | Distal Hereditary Motor Neuronopathy Type I | Distal Hereditary Motor Neuronopathy Type VIUnited Kingdom